sPLA2-III as a Biomarker in Colorectal Cancer
Author Information
Author(s): Mounier C M, Wendum D, Greenspan E, Fléjou J-F, Rosenberg D W, Lambeau G
Primary Institution: Institut de Pharmacologie Moléculaire et Cellulaire, CNRS-UNSA UMR6097, Sophia Antipolis, Valbonne, France
Hypothesis
Can the expression of secreted phospholipases A2 (sPLA2s) serve as biomarkers for human colorectal cancer?
Conclusion
The study suggests that sPLA2-III may be a novel biomarker for both left and right colon cancers.
Supporting Evidence
- PLA2G3 expression increased by up to 40-fold in adenocarcinomas.
- PLA2G2D and PLA2G5 expression decreased by up to 23- and 14-fold, respectively.
- The expression pattern of sPLA2s is linked to other genes associated with colon cancer.
- sPLA2-III was significantly upregulated in tumor tissues compared to normal mucosa.
Takeaway
Researchers looked at how certain proteins called sPLA2s behave in colon cancer and found that one of them, sPLA2-III, could help doctors tell if someone has cancer.
Methodology
The expression of sPLA2s was analyzed in tumor and normal tissues from patients using quantitative PCR and immunohistochemistry.
Potential Biases
Potential bias due to the limited sample size and the specific patient demographics.
Limitations
The study did not include rectal specimens and focused only on sporadic adenocarcinomas.
Participant Demographics
Patients aged 42 to 85 years, with a median age of 71, including 14 men and 7 women.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website